Homepage
Author:
Cardiff Oncology, Inc.
Posted Date:
March 20, 2026
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer
Cardiff Oncology, Inc.
March 20, 2026
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
Cardiff Oncology, Inc.
March 19, 2026
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
Cardiff Oncology, Inc.
February 26, 2026
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
Cardiff Oncology, Inc.
February 25, 2026
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Cardiff Oncology, Inc.
February 19, 2026
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
Cardiff Oncology, Inc.
January 28, 2026
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
Cardiff Oncology, Inc.
January 28, 2026
